Tighter Controls For Pseudoephedrine OTCs In France
Popular OTC drugs from J&J, Sanofi and Reckitt Benckiser are among those affected by new rules for the dispensing of pseudoephedrine-containing products in France following a spike in adverse events related to misuse of oral vasoconstrictors.
You may also be interested in...
With Consumer Healthcare sales down for Sanofi in 2019, CEO Hudson says the firm must do more to turn performance around. Key to achieving this will be the creation of a more agile standalone OTC business.
Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.
Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.